Migraine and Headache

Fremanezumab Effective in Patients With Difficult-to-Treat Migraine

By December 18, 2018

The FOCUS study enrolled a total of 838 patients who experienced chronic or episodic migraines and had inadequate responses (defined as lack of efficacy after at least 3 months of therapy; or the patient cannot tolerate the drug; or the drug is contraindicated; or the drug is not suitable for the patient) to other classes of drugs (ie, beta-blockers, anticonvulsants, tricyclics, calcium channel blockers, angiotensin II receptor antagonists, onabotulinumtoxinA, valproic acid).

Functional Nasal Surgery Can Improve Headache Symptoms

December 07, 2018

Surgery to remove nasal mucus contact points could reduce symptoms in patients with chronic headache.

Migraine Subtype Linked to Increased Risk of Incident Atrial Fibrillation

December 05, 2018

Migraine with aura is associated with an elevated risk for incident atrial fibrillation, according to a new study.

Rimegepant Zydis ODT Beneficial in Phase 3 Migraine Trial

By December 03, 2018

In Study 303 (N=1375), rimegepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist, achieved statistical significance in 2 co-primary endpoints: pain freedom and freedom from most bothersome symptom (MBS).

FDA Clears nVNS Therapy for Prevention of Cluster Headache

By November 29, 2018

The FDA clearance was based on data from 2 studies.

Lasmiditan NDA Submitted for Acute Treatment of Migraine

By November 14, 2018

The NDA submission included data from two Phase 3 trials, SAMURAI and SPARTAN.

Expert Opinion: CGRP Receptor Antagonist Use in Pediatric Patients With Migraine

By October 25, 2018

Recommendations on the use of these agents in this patient population were published in a Views and Perspectives paper in the journal Headache.

Migraine Prevention Treatment Emgality Gets FDA Approval

By September 28, 2018

The approval was based on data from 3 randomized, double-blind, placebo-controlled trials (EVOLVE-1, EVOLVE-2, REGAIN) in patients with either episodic or chronic migraine.

Ajovy Injection Approved for Migraine Prevention in Adults

By September 17, 2018

The primary efficacy endpoint was the mean change from baseline in the monthly average number of headache days of at least moderate severity during the 3-month treatment period.

New Device Available for Patients With Episodic Cluster Headache, Migraine

By August 02, 2018

The Sapphire has a rechargeable and reloadable fill capacity; it can be activated monthly by inputting a unique, prescription-only authorization code, delivered via a radio-frequency identification card that is mailed to the patient.

Butalbital/APAP Capsules Launched for Complex Tension Headache

By August 01, 2018

The label includes a Boxed Warning describing the risk of hepatotoxicity associated with APAP. Most cases of liver injury were associated with APAP doses >4000mg daily and often involved >1 APAP-containing product.

Risk of Cochlear Disorders Up With History of Migraine

July 18, 2018

For the migraine and non-migraine cohorts, the incidence rates of cochlear disorders were 81.4 and 29.4 per 1 million person-years, respectively.

OnabotulinumtoxinA Safer, More Effective for Headache Prevention Than Topiramate

June 29, 2018

This randomized, open-label study examined participant reported outcomes, safety, and tolerability of onabotulinumtoxinA and topiramate in adults with chronic migraines.

Fremanezumab Chronic Cluster Headache Study Discontinued

By June 15, 2018

Fremanezumab, an anti-CGRP monoclonal antibody, is currently being reviewed by the Food and Drug Administration (FDA) as a quarterly or monthly injection for the preventive treatment of migraine in adults.

Antiepileptic Treatment Shows Efficacy in Reducing Migraine Frequency

June 12, 2018

The antiepileptic drug levetiracetam may represent an effective prophylactic treatment option for episodic migraine.

Galcanezumab Beneficial for Patients With Episodic Migraine, Says Study

May 31, 2018

A total of 858 adults with at least a 1-year history of migraine, 4 to 14 migraine headache days per month, and a mean of at least 2 migraine attacks per month within the past 3 months received once-monthly treatments for 6 months and were followed up for 5 months after the last injection.

First-of-its-Kind Migraine Drug Gets FDA Approval

By May 18, 2018

The efficacy of Aimovig was evaluated as a preventive treatment of episodic or chronic migraine in 3 randomized, double-blind, placebo-controlled studies: 2 studies in patients with episodic migraine (4-14 migraine days per month) and 1 study in patients with chronic migraine (≥15 headache days per month with ≥8 migraine days per month).

Fremanezumab effective in preventing episodic migraine

May 17, 2018

In this randomized controlled trial, Fremanezumab slightly decreased the amount of headache free days in those with episodic migraines compared to placebo.

Fremanezumab Linked to Fewer Monthly Migraine Days

May 16, 2018

The researchers found that over 12 weeks, mean migraine days per month decreased from 8.9 to 4.9 days, from 9.2 to 5.3 days, and from 9.1 to 6.5 days in the fremanezumab monthly dosing group, the fremanezumab single-higher-dose group, and the placebo group, respectively.

Galcanezumab Effective in Phase 3 Episodic Cluster Headache Study

By May 15, 2018

The episodic cluster headache trial included a total of 106 patients with an average of 17.5 cluster headache attacks per week at baseline.

Antidepressant Medications and Headache: Is There a Link?

By May 03, 2018

Compared to placebo, selective serotonin reuptake inhibitors (SSRIs) were associated with a significantly higher risk of headache (risk ratio [RR] 1.06, 95% CI: 1.00 to 1.13; P =.045).

Results From Phase 3 Trial of Migraine Tx Ubrogepant Released

By April 27, 2018

Results showed that 14.3%, 20.7% (P=.0285), and 21.8% (P=.0129) achieved pain freedom in the placebo, ubrogepant 25mg dose, and 50mg dose groups, respectively.

Erenumab Shows Promise for Hard-to-Treat Migraine

April 19, 2018

"Our results show that people who thought their migraines were difficult to prevent may actually have hope of finding pain relief," Reuter said in a statement.

FDA-Approved App Allows Clinicians to Objectively Measure Balance

By April 18, 2018

The application assesses 3 key balance metrics: (1) double stance, (2) right tandem stance, and (3) left tandem stance.

Patient Develops Thunderclap Headaches After Consuming 'Carolina Reaper'

By April 10, 2018

The authors note that this appears to be the first case of RCVS secondary to pepper or cayenne ingestion.

Noninvasive Brain Stimulation May Help Prevent Migraines

April 04, 2018

"This open label study suggests that sTMS may be an effective, well-tolerated treatment option for migraine prevention," the authors write.

Novel Nasal Spray for Migraine Attacks to Be FDA Reviewed

By April 02, 2018

DFN-02 was evaluated in a multicenter, double-blind, randomized, placebo-controlled study (N=107) which showed it was effective in treating pain and associated symptoms during a migraine attack and in reducing attack-related functional disability.

Migraine Treatment With Needle-Free Delivery System No Longer Available

By February 27, 2018

Both strengths of Sumavel DosePro have now been discontinued.

Serotonin Syndrome Risk Assessed With Concomitant Triptan, SSRI/SNRI Use

February 27, 2018

Researchers question FDA advisory warning on risk of concomitant use

Positive Results for Ubrogepant in Phase 3 Migraine Trial

By February 06, 2018

A total of 1,327 migraine patients were treated in the study for a single migraine attack. At 2 hours after migraine attack, 19.2% (n=423) and 21.2% (n=448) of ubrogepant 50mg and 100mg were pain free, respectively.